Meyer Pharmaceuticals recently acquired rights to develop and market a new Oligonucleotide Decoy drug in North America and Europe.  The new drug specifically blocks pro-inflammatory genes activated by the NF‑κB transcription factor, and is currently in a Phase II trial in Japan.  Our development partner is AnGes MG, Inc.  Meyer’s lead product is MP40 for treatment of atopic dermatitis and psoriasis.

Meyer Pharmaceuticals, LLC is a biopharmaceutical company dedicated to researching and developing innovative therapies for the treatment of inflammatory diseases and related disorders. Our therapeutic targets (rheumatoid arthritis, osteoarthritis, severe plaque psoriasis, inflammatory bowel disease, and sepsis) afflict over 60 million people worldwide. 

Our business strategy is to use our state-of-the-art capabilities to identify, evaluate, research and develop products through proof-of-concept clinical testing.  We intend to pursue later stage clinical development, manufacturing, sales and marketing through strategic alliances with larger pharmaceutical or biotechnology partners.  We continue to in-license complementary technology to strengthen the current pipeline.  Our long-term plan is to develop products through all stages of clinical testing and to market our products.

Meyer Pharmaceuticals® is a registered service mark for pharmaceutical research, used by permission of Meyer Pharmaceuticals, LLC.

Meyer Pharmaceuticals is a wholly owned subsidiary of Meyer Holdings LP.